EE229 Cost-Effectiveness Analysis of Eremumab (Aimovig®) for the Preventive Treatment of Migraine in Spain

Dec 1, 2022, 00:00 AM

10.1016/j.jval.2022.09.477

https://www.valueinhealthjournal.com/article/S1098-3015(22)02681-X/fulltext

Section Title :

Section Order : 12285

First Page :

https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02681-X&doi=10.1016/j.jval.2022.09.477

HEOR Topics :

Tags :

Regions :